Veranova A CDMO that manages complexity with confidence

Veranova A CDMO that manages complexity with confidence

X

[{"orgOrder":0,"company":"Touchlight","sponsor":"Cancer Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cancer Research UK, University of Southampton and Touchlight Genetics Partner to Develop Head and Neck Cancer Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Touchlight","sponsor":"Versameb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Touchlight and Versameb Announce GMP Manufacturing Supply Agreement","therapeuticArea":"Urology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Urology","graph2":"Preclinical"},{"orgOrder":0,"company":"Touchlight","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Touchlight Signs Patent License Agreement with Pfizer for The Use of dbDNA For the Manufacture of mRNA-Based Vaccines, Therapeutics and Gene Therapies","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Touchlight","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Touchlight Announces Development of A Vaccine Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery"},{"orgOrder":0,"company":"Touchlight","sponsor":"Lonza Capsugel","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lonza and Touchlight Collaborate on End-To-End mRNA Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Touchlight","sponsor":"Voyager Therapeutics, Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Touchlight Signs License Agreement With Voyager for Use of Touchlight\u2019s DNA Technology in Voyager\u2019s Capsid Discovery Platform","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2022","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Touchlight","sponsor":"Odimma Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Touchlight and Odimma Therapeutics Announce Clinical Material Supply Agreement to Develop Personalised Cancer Therapy Utilising Doggybone DNA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"December 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Touchlight","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Touchlight Announces First FDA Clearance of an IND Utilising Doggybone DNA","therapeuticArea":"Technology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Technology","graph2":"IND Enabling"}]

Find Clinical Drug Pipeline Developments & Deals by Touchlight

Touchlight
Developments
Full Screen View

Touchlight

About, Contact Details

EVENTS

Webinars & Exhibitions

Webinars & Exhibitions

PRESENTATION(s)

dbDNA Catalogue Products, Touchlight signs patent license agreement with Pfizer, Enzymatic DNA for AAV Production, Enzymatic DNA for mRNA Production

VIDEO(s)

DNA Manufacturing Facility, doggybone DNA (dbDNA)

DIGITAL CONTENT

21 News

21 News

DEVELOPMENTS

8 Drug(s) in Development

8 Drug(s) in Development

SERVICES

All Services, Drug Product Manufacturing

All Services
Drug Product Manufacturing
- 11 Biologic Drugs

Developments

Filters

×

FILTER:

filter

Company

filter

Sponsor

filter

Country

filter

Therapeutic Area

filter

Study Phase

Active Filter(s):

Filters

Reset Filter

All Developments

Companies By Therapeutic Area

Development Status

Touchlight

Contact Supplier

The Making of DNA

Contact Supplier

Contact Supplier

Digital Content

Touchlight Announces First FDA Clearance of an IND Utilising Doggybone DNA

Details:

dbDNA technology produces a minimal, linear, double stranded, covalently closed DNA vector through an enzymatic manufacturing process. dbDNA will be used as an in vitro transcription template for mRNA production in the manufacturing of a cell therapy product.

Lead Product(s): Undisclosed

Therapeutic Area: Technology Product Name: Undisclosed

Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 28, 2023

Asia Pharmaceutics 2023

Not Confirmed

envelop

Contact Supplier

Touchlight

Contact Supplier

The Making of DNA

Contact Supplier

Contact Supplier

Digital Content

Touchlight and Odimma Therapeutics Announce Clinical Material Supply Agreement to Develop Personalised Cancer Therapy Utilising Doggybone DNA

Details:

Odimma will gain access to Touchlight’s proprietary doggybone DNA (dbDNA™) vector technology, providing them with a clinical supply of personalised dbDNA™, to support and underpin the development of their candidate immunotherapy cancer treatment.

Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Odimma Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement December 07, 2022

Asia Pharmaceutics 2023

Not Confirmed

envelop

Contact Supplier

Touchlight

Contact Supplier

The Making of DNA

Contact Supplier

Contact Supplier

Digital Content

Touchlight Signs License Agreement With Voyager for Use of Touchlight’s DNA Technology in Voyager’s Capsid Discovery Platform

Details:

Under the license agreement, Voyager gains rights to Touchlight’s DNA technology for use in the creation of novel capsids with the potential to power programs in Voyager’s pipeline and supporting Voyager alliances with leading biopharma partners.

Lead Product(s): Undisclosed

Therapeutic Area: Technology Product Name: Undisclosed

Highest Development Status: Discovery Platform Product Type: Undisclosed

Partner/Sponsor/Collaborator: Voyager Therapeutics, Inc

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement November 15, 2022

Asia Pharmaceutics 2023

Not Confirmed

envelop

Contact Supplier

Touchlight

Contact Supplier

The Making of DNA

Contact Supplier

Contact Supplier

Digital Content

Lonza and Touchlight Collaborate on End-To-End mRNA Offering

Details:

Under the terms of the agreement, Lonza can now provide its customers with seamless access to Touchlight’s enzymatic DNA technology; a linear, covalently closed DNA vector, produced using an enzymatic manufacturing process.

Lead Product(s): mRNA-based Vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Vaccine

Recipient: Lonza Capsugel

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration September 06, 2022

Asia Pharmaceutics 2023

Not Confirmed

envelop

Contact Supplier

Touchlight

Contact Supplier

The Making of DNA

Contact Supplier

Contact Supplier

Digital Content

Touchlight Signs Patent License Agreement with Pfizer for The Use of dbDNA For the Manufacture of mRNA-Based Vaccines, Therapeutics and Gene Therapies

Details:

Under the license agreement, Pfizer gains rights to Touchlight’s enzymatic doggybone DNA (dbDNA™) patent portfolio for worldwide use in Pfizer’s manufacture and commercialisation of its messenger RNA-based vaccines, therapeutics and gene therapies.

Lead Product(s): mRNA-based Vaccine

Therapeutic Area: Technology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Pfizer Inc

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement July 06, 2022

Asia Pharmaceutics 2023

Not Confirmed

envelop

Contact Supplier

Touchlight

Contact Supplier

The Making of DNA

Contact Supplier

Contact Supplier

Digital Content

Touchlight and Versameb Announce GMP Manufacturing Supply Agreement

Details:

The agreement enables Versameb to use Touchlight’s proprietary doggybone DNA (dbDNA™) vector technology to support the development of novel mRNA-based therapeutics, including VMB-100, addressing unmet needs in urology and oncology.

Lead Product(s): VMB-100

Therapeutic Area: Urology Product Name: VMB-100

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Versameb

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement March 01, 2022

Asia Pharmaceutics 2023

Not Confirmed

envelop

Contact Supplier

Touchlight

Contact Supplier

The Making of DNA

Contact Supplier

Contact Supplier

Digital Content

Touchlight Announces Development of A Vaccine Against COVID-19

Details:

The vaccine targets multiple viral antigens with the aim of generating an antibody and T-cell based immune response, whose breadth more closely mimics that of convalescent patients.

Lead Product(s): Undisclosed

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 21, 2020

Asia Pharmaceutics 2023

Not Confirmed

envelop

Contact Supplier

Touchlight

Contact Supplier

The Making of DNA

Contact Supplier

Contact Supplier

Digital Content

Cancer Research UK, University of Southampton and Touchlight Genetics Partner to Develop Head and Neck Cancer Vaccine

Details:

The new clinical development partnership aims at progressing a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC).

Lead Product(s): TGL-100

Therapeutic Area: Oncology Product Name: TGL-100

Highest Development Status: Preclinical Product Type: Vaccine

Recipient: Cancer Research

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership July 29, 2020

Asia Pharmaceutics 2023

Not Confirmed

envelop

Contact Supplier

POST ENQUIRY